Predictive and prognostic value of peripheral blood cytokeratin-19 mRNA-positive cells detected by real-time polymerase chain reaction in node-negative breast cancer patients

Journal of Clinical Oncology

Volumn 24, Issue 23, 2006, Pages 3756-3762

  Xenidis, Nikos ^a   Perraki, Maria ^a   Kafousi, Maria ^a   Apostolaki, Stella ^a   Bolonaki, Irene ^a   Stathopoulou, Aliki ^a   Kalbakis, Kostas ^a   Androulakis, Nikos ^a   Kouroussis, Charalambos ^a   Pallis, Thanos ^a   Christophylakis, Charalambos ^a   Argyraki, Katerina ^a   Lianidou, Evi S ^a   Stathopoulos, Stathis ^a   Georgoulias, Vassilis ^a   Mavroudis, Dimitris ^a  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; CYTOKERATIN 19; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; TAMOXIFEN; KERATIN; MESSENGER RNA; TUMOR MARKER;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; PREDICTION AND FORECASTING; PRIORITY JOURNAL; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; TREATMENT RESPONSE; BLOOD; BREAST TUMOR; CHEMISTRY; FEMALE; GENETICS; LYMPH NODE METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; POLYMERASE CHAIN REACTION; RECURRENT DISEASE; SURVIVAL; TIME; TUMOR RECURRENCE;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; HUMANS; KERATINS; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECURRENCE; RNA, MESSENGER; SURVIVAL ANALYSIS; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 33747341338     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.04.5948     Document Type: Article

References (32)

1. Mettlin C: Global breast cancer mortality statistics. Cancer J Clin 49:138-144, 1999
2. Bland KI, Menck HR, Scott-Connor CE, et al: The National Cancer Data Base 10-year survey of breast cancer treatment at hospitals in the United States. Cancer 83:1262-1273, 1998
3. Early Breast Cancer Trialists' Collaborative Group: Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 365:1687-1717, 2005
4. Early Breast Cancer Trialists' Collaborative Group: Polychemotherapy for early breast cancer: An overview of the randomised trials. Lancet 352: 930-942, 1998
5. Paget S. Distribution of secondary growths in cancer of the breast. Lancet 1:571, 1889
6. Dowlatshaui K, Fan M, Snider HC, et al: Lymph node micrometastases from breast carcinoma. Cancer 80:1188-1197, 1997
7. Fisher B, Fisher ER, Guzman C, et al: The dissemination of subcutaneously inoculated tumor cell suspensions. Arch Surg 98:347-351, 1968
8. Ménard S, Bufalino R, Rilke F, et al: Prognosis based on primary breast carcinoma instead of pathological nodal status. Br J Cancer 70:709-712, 1994
9. Pantel K, Cote RJ, Fodstad O: Detection and clinical importance of micrometastatic disease. J Natl Cancer Inst 91:1113-1124, 1999
10. Mansi JL, Gogas H, Bliss JM, et al: Outcome of primary breast cancer patients with micrometastases: A long-term follow-up. Lancet 354:197-202, 1999
11. Braun S, Pantel K, Muller P, et al: Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II or III breast cancer. N Engl J Med 342:525-533, 2000
12. Stathopoulou A, Vlachonicolis I, Mavroudis D, et al: Molecular detection of cytokeratin-19-positive cells in the peripheral blood of patients with operable breast cancer: Evaluation of their prognostic significance. J Clin Oncol 20:3404-3412, 2002
13. Wiedswang G, Borgen E, Karesen R, et al: Detection of isolated tumor cells in bone marrow is an independent prognostic factor in breast cancer. J Clin Oncol 21:3469-3478, 2003
14. Braun S, Vogl FD, Naume B, et al: A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med 353:793-802, 2005
15. Bernard P, Wittner CT: Real-time PCR technology for cancer diagnostics. Clin Chem 48:1178-1185, 2002
16. Bosma AJ, Weigelt B, Lambrechts AC, et al: Detection of circulating breast tumor cerlls by differential expression of marker genes. Clin Cancer Res 8:1871-1877, 2002
17. Zehenter BK, Dillon DC, Jiang Y, et al: Application of a multigene reverse transcription PCR assay for detection of mammaglobulin and complementary transcribed genes in breast cancer lymph nodes. Clin Chem 48:1225-1231, 2002
18. Stathopoulou A, Gizi A, Perraki M, et al: Real-time quantification of CK-19 mRNA-positive cells in peripheral blood of breast cancer patients using the LightCycler system. Clin Cancer Res 9:5145-5151, 2003
19. Cox DR: The Analysis of Binary Data. London, United Kingdom, Methuen, 1970
20. Collett D: Modelling Binary Data. London, United Kingdom, Chapman and Hall/CRC,
21. Collett D: Modeling Survival Data in Medical Research. London, United Kingdom, Chapman and Hall/CRC, 1999
22. Altman GD: Practical Statistics for Medical Research. London, United Kingdom, Chapman and Hall, 1991
23. Armitage P, Berry G: Statistical Methods in Medical Research (ed 3). Oxford, United Kingdom, Blackwell Scientific, 1994
24. Carter CL, Allen C, Henson DE: Relation of tumor size, lymph node status and survival in 24740 breast cancer cases. Cancer 63:181-187, 1989
25. Diell Kaufmann M, Costa SD, et al: Micrometastatic breast cancer cells in bone marrow at primary surgery: Prognostic value in comparison with nodal status. J Natl Cancer Inst 88:1652-1658, 1996
26. Gebauer G, Fehm T, Merkle E, et al: Epithelial cells in bone marrow of breast cancer patients at time of primary surgery: Clinical outcome during long-term follow-up. J Clin Oncol 19:3669-3674, 2001
27. Braun S, Kentenich CRM, Janni W, et al: Lack of effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in bone marrow of high risk breast cancer patients. J Clin Oncol 18:80-86, 2000
28. Xenidis N, Vlachonikolis I, Mavroudis D, et al: Peripheral blood circulating cytokeratin-19 mRNA-positive cells after the completion of adjuvant chemotherapy in patients with operable breast cancer. Ann Oncol 14:849-855, 2003
29. Braun S, Schlimok G, Heumos I, et al: ErbB2 overexpression on occult metastatic cells in bone marrow predicts poor clinical outcome of stage I-III breast cancer patients. Cancer Res 61:1890-1895, 2001
30. Heiss MM, Allgayer H, Gruetzner KU, et al: Individual development and uPA-receptor expression of disseminated tumour cells in bone marrow: A reference to early systemic disease in solid cancer. Nat Med 1:1035-1039, 1995
31. Offner S, Schmaus W, Witter K, et al: p53 gene mutations are not required for early dissemination of cancer cells. Proc Natl Acad Sci U S A 96:6942-6946, 1999
32. Bozionellou V, Mavroudis D, Perraki M, et al: Transtzumab administration can effectively target chemotherapy-resistant cytokeratin-19 messenger RNA-positive tumor cells in the peripheral blood and bone marrow of patients with breast cancer. Clin Cancer Res 10:8185-8194, 2004